Evidence map›Paper›PMID 23209384›Full record

ArticlePLoS medicine2012

Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis.

Daniel E Winetsky, Diana M Negoescu, Emilia H DeMarchis, Olga Almukhamedova, Aizhan Dooronbekova, Dilshod Pulatov, Natalia Vezhnina, Douglas K Owens, Jeremy D Goldhaber-Fiebert

Open access · goldAbstract readComparative Study
In one paragraph

Article in PLoS medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 13 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 13 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Article
  15. Review
  16. Article
  17. Article
  18. Abbott realtime MTB assay for detecting Mycobacterium tuberculosis complex in respiratory specimens: a cost-benefit analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  19. Article
  20. Population-based active screening strategy contributes to the prevention and control of tuberculosis.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Daniel E WinetskyStanford University School of Medicine, California, United States of America.
Diana M Negoescu
Emilia H DeMarchis
Olga Almukhamedova
Aizhan Dooronbekova
Dilshod Pulatov
Natalia Vezhnina
Douglas K Owens
Jeremy D Goldhaber-Fiebert
Aidsfonds · NLStanford University · USVA Palo Alto Health Care System · US

Funding

Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR01DA015612 · NIDA · STANFORD UNIVERSITY · PI OWENS, DOUGLAS K · 2002 to 2017
$9.4M
Cost-effective chronic disease prevention in developing countriesK01AG037593 · NIA · STANFORD UNIVERSITY · PI GOLDHABER-FIEBERT, JEREMY DAVID · 2011 to 2015
$637k
NIA NIH HHS K01 AG037593NIA NIH HHS K01 AG037593-01A1NIDA NIH HHS R01 DA015612NIDA NIH HHS R01DA015612
6 · The paper itself

Abstract

backgroundPrisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission. METHODS AND

findingsWe developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.

conclusionsIn prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time.

Indexed as

PrisonsAntibiotics, AntitubercularBaltic StatesClinical Laboratory TechniquesCommonwealth of Independent StatesCost-Benefit AnalysisDrug Resistance, BacterialEpidemicsHumansLatviaMass ScreeningModels, TheoreticalMycobacterium tuberculosisPrevalenceQuality-Adjusted Life YearsReal-Time Polymerase Chain ReactionAntibiotics, AntitubercularRifampin

Identifiers

PMID23209384
PMCPMC3507963
OpenAlexW2171167861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.